smartbax
smartbax is a German biotech startup founded in Munich in 2021, dedicated to developing innovative antibiotics to combat the rising threat of multi-drug-resistant bacteria. Their mission is to create smarter antibiotics for a healthier tomorrow by combining cutting-edge technology with deep scientific expertise to outsmart bacterial resistance. They focus on substances that address multiple targets to hinder resistance development and specialize in tailored activation of enzymatic pathways, especially in difficult-to-treat biofilms. Their research is based on revolutionary discoveries from TU Munich, aiming to develop a new generation of antibiotics with unprecedented modes of action to fight multi-drug resistant pathogens.
Industries
Nr. of Employees
small (1-50)
smartbax
Products
Small-molecule antibacterial candidates (enzyme-activation mechanism)
Preclinical small-molecule drug candidates that employ enzyme-activation and multi-target mechanisms to kill multidrug-resistant bacteria, including activity against biofilms and persister cells; efficacy reported in animal models.
Small-molecule antibacterial candidates (enzyme-activation mechanism)
Preclinical small-molecule drug candidates that employ enzyme-activation and multi-target mechanisms to kill multidrug-resistant bacteria, including activity against biofilms and persister cells; efficacy reported in animal models.
Services
Collaborative research and translation agreements with academic groups and industry partners to develop antibacterial candidates originating from academic discovery.
Collaborative research and translation agreements with academic groups and industry partners to develop antibacterial candidates originating from academic discovery.
Expertise Areas
- Antibiotic discovery
- Preclinical drug development
- Mechanism-of-action research
- Biofilm and persister-targeted therapeutics
Key Technologies
- Small-molecule antibacterial chemistry
- Enzyme-activation therapeutic approach
- Multi-target mode-of-action elucidation
- Biofilm and persister cell assays
News & Updates
May 2023 - smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics
smartbax closed a seed financing round of €1.2 million from BIVF and HTGF, bringing total capital to €1.9 million. The funds will be used to advance small molecule antibiotics through preclinical studies, expand the scientific team, and develop solutions against multi-drug resistant pathogens. Their product candidates act via a unique, double-targeted mechanism of action, inhibiting energy metabolism and stimulating bacterial self-digestion.
May 2023 - smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics
smartbax closed a seed financing round of €1.2 million from BIVF and HTGF, bringing total capital to €1.9 million. The funds will be used to advance small molecule antibiotics through preclinical studies, expand the scientific team, and develop solutions against multi-drug resistant pathogens. Their product candidates act via a unique, double-targeted mechanism of action, inhibiting energy metabolism and stimulating bacterial self-digestion.